As of November 10, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Quoin Pharmaceuticals Ltd. The largest reported stake is Stonepine Capital Management, LLC's, at 9.99%. 16 filings are on record since October 27, 2025 (Schedule 13G/A, May 15, 2026).
Sell to companies like Quoin Pharmaceuticals Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Ikarian Capital, LLC · Sole voting: 0 · Shared voting: 211,538 · Sole dispositive: 0 · Shared dispositive: 211,538 · SCHEDULE 13G/A, 2026-10-07
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 3,850,385 · Sole dispositive: 0 · Shared dispositive: 3,850,385 · SCHEDULE 13G, 2026-06-02
- · Holder: Woodline Partners LP · Percent: 4.4% · SCHEDULE 13G/A
- · Holder: Stonepine Capital Management, LLC · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: ADAR1 Capital Management, LLC · Percent: 4.9% · SCHEDULE 13G/A
Quoin Pharmaceuticals Ltd. has 16 Schedule 13D or 13G filings on record since 2025-10-27. 3 holders' latest filing reports 5% or more of american depositary shares, each representing thirty-five (35) ordinary shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Stonepine Capital Management, LLC | 9.99% | 7,594,166 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Resolute Capital Asset Partners LLC | 8.5% | 50,000 | SCHEDULE 13G, 2025-12-11 | 2025-10-10 |
| Integrated Core Strategies (US) LLC | 5.5% | 3,850,385 | SCHEDULE 13G, 2026-06-02 | 2026-05-26 |
| ADAR1 Capital Management, LLC | 4.9% | 102,846 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Ikarian Capital, LLC | 4.4% | 211,538 | SCHEDULE 13G/A, 2026-10-07 | 2026-09-30 |
| Woodline Partners LP | 4.4% | 2,785,370 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Aberdeen Group plc | 4.16% | 75,000 | SCHEDULE 13G/A, 2026-04-29 | 2026-04-01 |
Holding shares or following this stake? See who's behind Quoin Pharmaceuticals Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on Quoin Pharmaceuticals Ltd. and the records around it.
Quoin Pharmaceuticals Ltd. elsewhere on the record
- Company profile and every filing Sep 2026
- Form D filing Sep 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
- Stonepine Capital Management, LLC also filed stake reports on 17 other companies: Femasys Inc (Aug 2026), Edesa Biotech, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
Watch Quoin Pharmaceuticals Ltd.
Get an email when Quoin Pharmaceuticals Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Quoin Pharmaceuticals Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Quoin Pharmaceuticals Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Quoin Pharmaceuticals Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Integrated Core Strategies (US) LLC | 0 | 3,850,385 | 0 | 3,850,385 | SCHEDULE 13G, 2026-06-02 |
| Millennium Management LLC | 0 | 3,850,385 | 0 | 3,850,385 | SCHEDULE 13G, 2026-06-02 |
| Millennium Group Management LLC | 0 | 3,850,385 | 0 | 3,850,385 | SCHEDULE 13G, 2026-06-02 |
| Israel A. Englander | 0 | 3,850,385 | 0 | 3,850,385 | SCHEDULE 13G, 2026-06-02 |
| Ikarian Capital, LLC | 0 | 211,538 | 0 | 211,538 | SCHEDULE 13G/A, 2026-10-07 |
| Neil Shahrestani | 0 | 211,538 | 0 | 211,538 | SCHEDULE 13G/A, 2026-10-07 |
The latest filing identifies Quoin Pharmaceuticals Ltd. by CUSIP 74907L409 and gives its principal executive office as 42127 Pleasant Forest Court, Ashburn, VA 20148-7349 (SCHEDULE 13G/A, 2026-10-07).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-27 | Integrated Core Strategies (US) LLC | 9% | SCHEDULE 13G |
| 2025-12-11 | Resolute Capital Asset Partners LLC | 8.5% | SCHEDULE 13G |
| 2025-12-15 | Ikarian Capital, LLC | 25.2% | SCHEDULE 13G |
| 2025-12-16 | Stonepine Capital Management, LLC | 9.9% | SCHEDULE 13G |
| 2026-01-28 | Aberdeen Group plc | 8.94% | SCHEDULE 13G |
| 2026-02-02 | Stonepine Capital Management, LLC | 10.6% | SCHEDULE 13G/A |
| 2026-02-06 | Ikarian Capital, LLC | 12.6% | SCHEDULE 13G/A |
| 2026-02-11 | Integrated Core Strategies (US) LLC | 4.6% | SCHEDULE 13G/A |
| 2026-02-17 | Woodline Partners LP | 9.5% | SCHEDULE 13G |
| 2026-02-17 | ADAR1 Capital Management, LLC | 6.9% | SCHEDULE 13G |
| 2026-04-29 | Aberdeen Group plc | 4.16% | SCHEDULE 13G/A |
| 2026-05-15 | Woodline Partners LP | 4.4% | SCHEDULE 13G/A |
| 2026-05-15 | Stonepine Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-05-15 | ADAR1 Capital Management, LLC | 4.9% | SCHEDULE 13G/A |
| 2026-06-02 | Integrated Core Strategies (US) LLC | 5.5% | SCHEDULE 13G |
| 2026-10-07 | Ikarian Capital, LLC | 4.4% | SCHEDULE 13G/A |
Questions about who owns Quoin Pharmaceuticals Ltd.
Who owns Quoin Pharmaceuticals Ltd.?
On this page, 3 holders' latest ownership filings report 5% or more of Quoin Pharmaceuticals Ltd.: Stonepine Capital Management, LLC (9.99%, Schedule 13G/A, filed 2026-05-15), Resolute Capital Asset Partners LLC (8.5%, Schedule 13G, filed 2025-12-11) and Integrated Core Strategies (US) LLC (5.5%, Schedule 13G, filed 2026-06-02).
Who are the largest shareholders of Quoin Pharmaceuticals Ltd.?
By the share each holder's latest filing reports, the largest holders of Quoin Pharmaceuticals Ltd. on this page are Stonepine Capital Management, LLC (9.99%), Resolute Capital Asset Partners LLC (8.5%) and Integrated Core Strategies (US) LLC (5.5%).
When did Stonepine Capital Management, LLC buy into Quoin Pharmaceuticals Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Stonepine Capital Management, LLC on this page is the Schedule 13G, filed 2025-12-16, reporting 9.9%; its latest, Schedule 13G/A filed 2026-05-15, reports 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Quoin Pharmaceuticals Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 10, 2026 | Form D, private offering | $50M sold | Form D page | Source |
| October 23, 2025 | Form D, private offering | $105.25M sold | Form D page | Source |
Quoin Pharmaceuticals Ltd.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Quoin Pharmaceuticals Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.